Review Article
Autoimmune Neutropenia Updates: Etiology, Pathology, and Treatment
Abstract
Autoimmune neutropenia (AIN) is defined as a neutrophil count <1.5 x 109/L caused by increased peripheral destruction of neutrophils from an underlying autoimmune mechanism in which autoantibodies are directed against a patient’s own neutrophils. AIN has a multifactorial etiology ranging from an idiopathic primary phenomenon to secondary disorders associated with established autoimmune diseases. Primary AIN is more prevalent in children, generally self-limited, and typically manifests as a sole hematologic abnormality. Secondary AIN is more common in adults and often occurs in the setting of concurrent autoimmune diseases, infections, malignancies, or medications. It may be seen posttransplantation or occasionally with neurological diseases. Various laboratory modalities are used to detect anti-neutrophil antibodies. Although biologic agents such as rituximab and alemtuzumab (Campath-1H) have been used in the management of AIN, granulocyte colony-stimulating factor remains the first-line therapy. In this article we provide a review of the pathogenesis of AIN, its clinical presentation, and the current treatment options.This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Bux J, Behrens G, Jaeger G, et al. Diagnosis and clinical course of autoimmune neutropenia in infancy: analysis of 240 cases. Blood 1998;91:181-186.
2. Lyall EG, Lucas GF, Eden OB. Autoimmune neutropenia of infancy. J Clin Pathol 1992;45:431-434.
3. Farruggia P, Dufour C. Diagnosis and management of primary autoimmune neutropenia in children: insights for clinicians. Ther Adv Hematol 2015;6:15-24.
4. Lalezari P, Khorshidi M, Petrosova M. Autoimmune neutropenia of infancy. J Pediatr 1986;109:764-769.
5. Wang LY, Wang CL, Chu CC, et al. Primary autoimmune neutropenia in children in Taiwan. Transfusion 2009;49:1003-1006.
6. Akhtari M, Curtis B, Waller EK. Autoimmune neutropenia in adults. Autoimmun Rev 2009;9:62-66.
7. Mariotti J, Caberlon S, Bertinato E, et al. Primary autoimmune neutropenia in adults: case report and review of the literature. Transfusion 2014;54:2906-2910.
8. Papadaki HA, Xylouri I, Coulocheri S, et al. Prevalence of chronic idiopathic neutropenia of adults among an apparently healthy population living on the island of Crete. Ann Hematol 1999;78:293-297.
9. Boxer LA, Greenberg MS, Boxer GJ, et al. Autoimmune neutropenia. N Engl J Med 1975;293:748-753.
10. Lalezari P, Jiang AF, Yegen L, et al. Chronic autoimmune neutropenia due to anti-NA2 antibody. N Engl J Med 1975;293:744-747.
11. Newman KA, Akhtari M. Management of autoimmune neutropenia in Felty’ syndrome and systemic lupus erythematosus. Autoimmun Rev 2011;10:432-437.
12. Lalezari P. Neutropenia. In: Rose NR, Mackay IR,, eds. The Autoimmune Diseases. 4th ed. St Louis: Elsevier, 2006:585-589.
13. Logue GL, Shastri KA, Laughlin M, et al. Idiopathic neutropenia: antineutrophil antibodies and clinical correlations. Am J Med 1991;90:211-216.
14. Durand V, Renaudineau Y, Pers JO, et al. Cross-linking of human FcgammaRIIIb induces the production of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor by polymorphonuclear neutrophils. J Immunol 2001;167:3996-4007.
15. Shastri KA, Logue GL. Autoimmune neutropenia. Blood 1993;81:1984-1995.
16. Moritz E, Norcia AM, Cardone JD, et al. Human neutrophil alloantigens systems. An Acad Bras Cienc 2009;81:559-569.
17. Reil A, Sachs UJ, Siahanidou T, et al. HNA-1d: a new human neutrophil antigen located on Fcγ receptor IIIb associated with neonatal immune neutropenia. Transfusion 2013;53:2145-2151.
18. Lalezari P, Murphy GB, Allen FH, Jr. NB1, a new neutrophil-specific antigen involved in the pathogenesis of neonatal neutropenia. J Clin Invest 1971;50:1108-1115.
19. Sachs UJ, Andrei-Selmer CL, Maniar A, et al. The neutrophil-specific antigen CD177 is a counter-receptor for platelet endothelial cell adhesion molecule-1 (CD31). J Biol Chem 2007;282:23603-23612.
20. Berthold T, Glaubitz M, Muschter S, et al. Human neutrophil antigen-3a antibodies induce neutrophil stiffening and conformational activation of CD11b without shedding of L-selectin. Transfusion 2015;55:2939-2948.
21. Wlodarski MW, Nearman Z, Jiang Y, et al. Clonal predominance of CD8(+) T cells in patients with unexplained neutropenia. Exp Hematol 2008;36:293-300.
22. Grayson PC, Sloan JM, Niles JL, et al. Antineutrophil cytoplasmic antibodies, autoimmune neutropenia, and vasculitis. Semin Arthritis Rheum 2011;41:424-433.
23. Akamizu T, Ozaki S, Hiratani H, et al. Drug-induced neutropenia associated with anti-neutrophil cytoplasmic antibodies (ANCA): possible involvement of complement in granulocyte cytotoxicity. Clin Exp Immunol 2002;127:92-98.
24. Nossent JC, Swaak AJ. Prevalence and significance of haematological abnormalities in patients with systemic lupus erythematosus. Q J Med 1991;80:605-612.
25. Newman K, Owlia MB, El-Hemaidi I, et al. Management of immune cytopenias in patients with systemic lupus erythematosus-old and new. Autoimmun Rev 2013;12:784-791.
26. Courtney PA, Crockard AD, Williamson K, et al. Increased apoptotic peripheral blood neutrophils in systemic lupus erythematosus: relations with disease activity, antibodies to double stranded DNA, and neutropenia. Ann Rheum Dis 1999;58:309-314.
27. Ren Y, Tang J, Mok MY, et al. Increased apoptotic neutrophils and macrophages and impaired macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus. Arthritis Rheum 2003;48:2888-2897.
28. Brito-Zerón P, Soria N, Muñoz S, et al. Prevalence and clinical relevance of autoimmune neutropenia in patients with primary Sjögren's syndrome. Semin Arthritis Rheum 2009;38:389-395.
29. Kurien BT, Newland J, Paczkowski C, et al. Association of neutropenia in systemic lupus erythematosus (SLE) with anti-Ro and binding of an immunologically cross-reactive neutrophil membrane antigen. Clin Exp Immunol 2000;120:209-217.
30. Mackworth-Young C. Primary antiphospholipid syndrome: a distinct entity? Autoimmun Rev 2006;5:70-75.
31. Starkebaum G, Arend WP, Nardella FA, et al. Characterization of immune complexes and immunoglobulin G antibodies reactive with neutrophils in the sera of patients with Felty’ syndrome. J Lab Clin Med 1980;96:238-251.
32. Meliconi R, Uguccioni M, Chieco-Bianchi F, et al. The role of interleukin-8 and other cytokines in the pathogenesis of Felty’ syndrome. Clin Exp Rheumatol 1995;13:285-291.
33. Dwivedi N, Radic M. Neutrophil activation and B-cell stimulation in the pathogenesis of Felty’ syndrome. Pol Arch Med Wewn 2012;122:374-379.
34. Liu X, Loughran TP, Jr. The spectrum of large granular lymphocyte leukemia and Felty's syndrome. Curr Opin Hematol 2011;18:254-259.
35. Waugh D, Ibels L. Malignant scleroderma associated with autoimmune neutropenia. Br Med J 1980;280:1577-1578.
36. Bux J, Robertz-Vaupel GM, Glasmacher A, et al. Autoimmune neutropenia due to NA1 specific antibodies in primary biliary cirrhosis. Br J Haematol 1991;77:121-122.
37. Sato S, Irisawa A, Sato A, et al. Autoimmune neutropenia associated with autoimmune pancreatitis. JOP 2011;12:407-409.
38. Leonard RC, Thompson RB. Behcet's syndrome and neutropenia. Postgrad Med J 1981;57:448-449.
39. Demiroğlu H, Dündar S. Behcet’s disease and chronic neutropenia. Scand J Rheumatol 1997;26:130-132.
40. Weitzman SA, Stossel TP, Harmon DC, et al. Antineutrophil autoantibodies in Graves’ disease. Implications of thyrotropin binding to neutrophils. J Clin Invest 1985;75:119-123.
41. Kozuka T, Kojima K, Kaneda K, et al. Autoimmune neutropenia associated with multiple sclerosis. Intern Med 2003;42:102-104.
42. Cunningham-Rundles C. How I treat common variable immune deficiency. Blood 2010;116:7-15.
43. Michel M, Chanet V, Galicier L, et al. Autoimmune thrombocytopenic purpura and common variable immunodeficiency: analysis of 21 cases and review of the literature. Medicine (Baltimore) 2004;83:254-263.
44. Brandt D, Gershwin ME. Common variable immune deficiency and autoimmunity. Autoimmun Rev 2006;5:465-470.
45. Michel M, Chanet V, Dechartres A, et al. The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. Blood 2009;8:3167-3172.
46. Aladjidi N, Fernandes H, Leblanc T, et al. Evans syndrome in children: long-term outcome in a prospective French national observational cohort. Front Pediatr 2015;3:79.
47. Deutsch M, Tsopanou E, Dourakis SP. The autoimmune lymphoproliferative syndrome (Canale-Smith) in adulthood. Clin Rheumatol 2004;23:43-44.
48. Straus SE, Jaffe ES, Puck JM, et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood 2001;98:194-200.
49. Ribera E, Ocana I, Almirante B, et al. Autoimmune neutropenia and thrombocytopenia associated with development of antibodies to human immunodeficiency virus. J Infect 1989;18:167-170.
50. Aaron L, Kahn JE, Therby A, et al. HHV 8 positive Castleman’s disease and auto-immune neutropenia in 2 HIV-infected patients. Rev Med Interne 2003;24:748-752.
51. von Landenberg P, Lehmann HW, Modrow S. Human parvovirus B19 infection and antiphospholipid antibodies. Autoimmun Rev 2007;6:278-285.
52. d'Alteroche L, Assor P, Lefrou L, et al. Severe autoimmune neutropenia and thrombopenia associated with chronic C hepatitis: effect of antiviral therapy. Gastroenterol Clin Biol 2005;29:297-299.
53. Ciufu C, Arama V, Bumbea H, et al. Correlations of hematological parameters with bone marrow findings in chronic lymphoproliferative disorders associated with hepatitis viruses. J Med Life 2013;6:464-471.
54. Gupta V, Eden AJ, Mills MJ. Helicobacter pylori and autoimmune neutropenia. Clin Lab Haematol 2002;24:183-185.
55. Heyman MR, Walsh TJ. Autoimmune neutropenia and Hodgkin’s disease. Cancer 1987;59:1903-1905.
56. Cartron J, Fior R, Boué F, et al. Non-Hodgkin's lymphoma presenting as neutropenia related to an IgM monoclonal anti-i antibody. Hematol Cell Ther 1996;38:225-230.
57. Visco C, Barcellini W, Maura F, et al. Autoimmune cytopenias in chronic lymphocytic leukemia. Am J Hematol 2014;89:1055-1062.
58. Ghia P, Scielzo C, Frenquelli M, et al. From normal to clonal B cells: chronic lymphocytic leukemia (CLL) at the crossroad between neoplasia and autoimmunity. Autoimmun Rev 2007;7:127-131.
59. Aryal MR, Bhatt VR, Tandra P, et al. Autoimmune neutropenia in multiple myeloma and the role of clonal T-cell expansion: evidence of cross-talk between B-cell and T-cell lineages? Clin Lymphoma Myeloma Leuk 2014;14:e19-e23.
60. Degos L, Faille A, Housset M, et al. Syndrome of neutrophil agranulocytosis, hypogammaglobulinemia, and thymoma. Blood 1982;60:968-972.
61. El-Galaly TC, Gregersen H, Bukh A. Good’ syndrome with lymphopenia and neutropenia. Ugesker Laeger 2011;173:280-281.
62. White JD, MacPherson IR, Evans TR. Auto-immune neutropenia occurring in association with malignant melanoma. Oncol Rep 2003;10:249-251.
63. Trebo MM, Thorner PS, Weitzman S. Wilms tumor and autoimmune neutropenia. Med Pediatr Oncol 2000;34:299-300.
64. Alliot C, Barrios M, Tabuteau S, et al. Autoimmune cytopenias associated with malignancies and successfully treated with intravenous immune globulins: about two cases. Therapie 2000;55:371-374.
65. Harada S, Yamazaki S, Nakamura F, et al. Autoimmune neutropenia preceding Helicobacter pylori -negative MALT lymphoma with nodal dissemination. Int J Clin Exp Pathol 2014;7:6386-6390.
66. Klumpp TR, Herman JH, Macdonald JS, et al. Autoimmune neutropenia following peripheral blood stem cell transplantation. Am J Hematol 1992;41:215-217.
67. Bohgaki T, Atsumi T, Koike T. Autoimmune disease after autologous hematopoietic stem cell transplantation. Autoimmun Rev 2008;7:198-203.
68. Gorski A. Autoimmune neutropenia after renal transplantation. Transplantation 1989;47:927.
69. Jondeau G, Bierling P, Rossert J, et al. Autoimmune neutropenia after renal transplantation. Transplantation 1988;46:589-591.
70. Aubert O, Sberro-Soussan R, Scemla A, et al. Autoimmune neutropenia after kidney transplantation: a disregarded entity of posttransplant neutropenia. Transplantation 2014;97:725-729.
71. Holland K, Spivak JL. Drug-induced immunological disorders of the blood. In: Newcombe DS, Rose NR, Bloom JC, , eds. Clinical Immunotoxicology. New York: Raven Press, 1992:141-153.
72. Gibson C, Berliner N. How we evaluate and treat neutropenia in adults. Blood 2014;124:1251-1258.
73. Rolston KV. Management of infections in the neutropenic patient. Annu Rev Med 2004;55:519-526.
74. Ito T, Taniuchi S, Tsuji S, et al. Diagnosis of autoimmune neutropenia by neutrophil-bound IgG and IgM antibodies. J Pediatr Hematol Oncol 2011;33:552-555.
75. Sella R, Flomenblit L, Goldstein I, et al. Detection of anti-neutrophil antibodies in autoimmune neutropenia of infancy: a multicenter study. Isr Med Assoc J 2010;12:91-96.
76. Fioredda F, Calvillo M, Burlando O, et al. Infectious complications in children with severe congenital, autoimmune or idiopathic neutropenia: a retrospective study from the Italian Neutropenia Registry. Pediatr Infect Dis J 2013;32:410-412.
77. Luca G, Rogers S, de Haas M, et al. Report on the Fourth International Granulocyte Immunology Workshop: progress toward quality assessment. Transfusion 2002;42:462-468.
78. Bux J, Kober B, Kiefel V, et al. Analysis of granulocyte-reactive antibodies using an immunoassay based upon monoclonal-antibody-specific immobilization of granulocyte antigens. Transfus Med 1993;3:157-162.
79. Bux J, Chapman J. Report on the second international granulocyte serology workshop. Transfusion 1997;37:977-983.
80. Heinzl MW, Schönbacher M, Dauber EM, et al. Detection of granulocyte-reactive antibodies: a comparison of different methods. Vox Sang 2015;108:287-293.
81. Lane SW, Hassell P, Kennedy GA, et al. Characterization of the bone marrow immunofluorescence test in childhood autoimmune neutropenia. Int J Lab Hematol 2009;31:567-571.
82. Logue GL, Huang AT, Shimm DS. Failure of splenectomy in Felty’s syndrome. The role of antibodies supporting granulocyte lysis by lymphocytes. N Engl J Med 1981;304:580-583.
83. Barnes ML, Saving KL, Vats TS. Post-splenectomy sepsis. Kans Med 1987;88:119-120, 124.
84. Fiechtner JJ, Miller DR, Starkebaum G. Reversal of neutropenia with methotrexate treatment in patients with Felty’s syndrome. Correlation of response with neutrophil-reactive IgG. Arthritis Rheum 1989;32:194-201.
85. Brucker R, Schlumpf U. Felty syndrome: a therapy-resistant variant of chronic rheumatoid arthritis? 2 case reports and literature review. Praxis (Bern 1994) 1996;85:534-540. Article in German.
86. Martino R, Sureda A, Ayats R, et al. Successful treatment of chronic autoimmune neutropenia with cyclosporin A. Haematologica 1994;79:66-69.
87. Ghnaya H, Bekov K, Jira M, et al. Primary chronic autoimmune neutropenia successfully treated with sirolimus. Rev Med Interne 2008;29:940-942. Article in French.
88. Cottle TE, Fier CJ, Donadieu J, et al. Risk and benefit of treatment of severe chronic neutropenia with granulocyte colony-stimulating factor. Semin Hematol 2002;39:134-140.
89. Schliesser G, Pralle H, Lohmeyer J. Leukocytoclastic vasculitis complicating granulocyte colony-stimulating factor (G-CSF) induced neutrophil recovery in T gamma-lymphocytosis with severe neutropenia. Ann Hematol 1992;65:151-152.
90. Ippoliti G, Paulli M, Lucioni M, et al. Leukocytoclastic vasculitis as a complication of recombinant granulocyte colony-stimulating factor therapy in a heart transplant patient. Case Rep Transplant 2014;2014:160407.
91. Verhoeven F, Guillot X, Prati C, et al. Treatment of pseudo Felty’s syndrome: is there a place for rituximab? Joint Bone Spine 2015;82:196-199.
92. Dungarwalla M, Marsh JC, Tooze JA, et al. Lack of clinical efficacy of rituximab in the treatment of autoimmune neutropenia and pure red cell aplasia: implications for their pathophysiology. Ann Hematol 2007;86:191-197.
93. Killick SB, Marsh JC, Hale G, et al. Sustained remission of severe resistant autoimmune neutropenia with Campath-1H. Br J Haematol 1997;97:306-308.
94. Marsh JC, Gordon-Smith EC. CAMPATH-1H in the treatment of autoimmune cytopenias. Cytotherapy 2001;3:189-195.
95. Willis F, Marsh JC, Bevan DH, et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol 2001;114:891-898.
